According to one Harvard Business Review article (see www.hbr.org/2015/09/its-time-to-rein-in-exorbitant -pharmaceutical-prices), over the past five years returns for the S&P Pharmaceuticals Select Industry Index have been virtually doubled those of the broader S&P 500 (roughly 24 percent versus 12 percent annually). What factors affect profitability in the pharmaceutical industry? Are these high profit levels a good or bad thing? Explain.